COVID-19 Antibody Tests Perform Well in Head-to-Head Comparison | Infectious Diseases | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

COVID-19 Antibody Tests Perform Well in Head-to-Head Comparison

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

Four widely used severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests had high sensitivity and specificity in what scientists said was the first large head-to-head comparison of commercial immunoassays developed during the coronavirus disease 2019 (COVID-19) pandemic.

The study, funded by Public Health England and the UK National Institute for Health Research, assessed the performance of high-throughput immunoassays from Abbott, DiaSorin, Roche, and Siemens, as well as an Oxford University–developed test. Researchers evaluated the assays using the same set of adult blood samples, which included 976 prepandemic samples and 536 samples from patients with polymerase chain reaction–confirmed SARS-CoV-2 infection. Except for the DiaSorin assay, all the tests would have an error rate of less than 1% at a seroprevalence of 10%, the researchers reported in The Lancet Infectious Diseases.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Four widely used severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests had high sensitivity and specificity in what scientists said was the first large head-to-head comparison of commercial immunoassays developed during the coronavirus disease 2019 (COVID-19) pandemic.

The study, funded by Public Health England and the UK National Institute for Health Research, assessed the performance of high-throughput immunoassays from Abbott, DiaSorin, Roche, and Siemens, as well as an Oxford University–developed test. Researchers evaluated the assays using the same set of adult blood samples, which included 976 prepandemic samples and 536 samples from patients with polymerase chain reaction–confirmed SARS-CoV-2 infection. Except for the DiaSorin assay, all the tests would have an error rate of less than 1% at a seroprevalence of 10%, the researchers reported in The Lancet Infectious Diseases.

If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close